1,029,860 Sanofi $SNY Shares Sold by Fisher Asset Management LLC

Key Points

• Fisher Asset Management cut its Sanofi stake by 9.7%, selling 1,029,860 shares in the third quarter. It still held 9.6 million shares, valued at about $395.7 million.
• Sanofi reported quarterly EPS of $2.04, beating the $1.56 consensus estimate, while revenue of $17.25 billion exceeded forecasts and rose 16.2% year over year.
• Analysts’ overall rating was Hold, with an average price target of $53; eight analysts rated the stock Buy and twelve rated it Hold.

Fisher Asset Management LLC lowered its position in Sanofi (NASDAQ:SNY - Free Report) by 9.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,597,228 shares of the company's stock after selling 1,029,860 shares during the period. Fisher Asset Management LLC owned approximately 0.40% of Sanofi worth $395,694,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Western Wealth Management LLC acquired a new stake in Sanofi in the first quarter valued at approximately $29,000. Root Financial Partners LLC purchased a new position in Sanofi in the third quarter worth $27,000. Signature Equity Partners LLC increased its position in shares of Sanofi by 322.2% during the third quarter. Signature Equity Partners LLC now owns 857 shares of the company's stock worth $35,000 after purchasing an additional 654 shares in the last quarter. Financial Network Wealth Advisors LLC increased its position in shares of Sanofi by 103.3% during the third quarter. Financial Network Wealth Advisors LLC now owns 911 shares of the company's stock worth $38,000 after purchasing an additional 463 shares in the last quarter. Finally, Provenance Wealth Advisors LLC increased its position in shares of Sanofi by 359.8% during the third quarter. Provenance Wealth Advisors LLC now owns 2,322 shares of the company's stock worth $96,000 after purchasing an additional 1,817 shares in the last quarter. Institutional investors own 14.03% of the company's stock.

Sanofi Trading Up 0.1%

Shares of Sanofi stock opened at $48.46 on Friday. The firm's 50 day simple moving average is $42.60 and its two-hundred day simple moving average is $44.37. The firm has a market capitalization of $117.49 billion, a price-to-earnings ratio of 23.99, a PEG ratio of 1.33 and a beta of 0.31. Sanofi has a 12-month low of $39.07 and a 12-month high of $52.68. The company has a current ratio of 1.12, a quick ratio of 0.27 and a debt-to-equity ratio of 0.20.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.56 by $0.48. The business had revenue of $17.25 billion during the quarter, compared to the consensus estimate of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The business's revenue for the quarter was up 16.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.91 earnings per share. Analysts predict that Sanofi will post 5.07 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on SNY shares. Weiss Ratings upgraded Sanofi from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, November 2nd. Deutsche Bank restated a "buy" rating on shares of Sanofi in a research note on Tuesday, September 29th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Sanofi in a research report on Thursday, October 1st. DZ Bank reiterated a "buy" rating on shares of Sanofi in a research note on Friday, July 31st. Finally, UBS Group reissued a "neutral" rating on shares of Sanofi in a report on Thursday, September 17th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $53.00.

Sanofi Company Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company's portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.